MANDI LAHMAN: Open Payments
NPI 1629461009 · MILLSBORO, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,039 in 56 payments from 16 companies in 2025. Trend: 2023 $818 · 2024 $792 · 2025 $1,039
Food & beverage: $1,039
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $159 |
| Novo Nordisk Inc | 7 | $124 |
| Merck Sharp & Dohme LLC | 5 | $121 |
| PFIZER INC. | 6 | $107 |
| Lilly USA, LLC | 4 | $88 |
| Abbott Laboratories | 4 | $76 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Amgen Inc. | 3 | $53 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $38 |
Products named: Ozempic, MOUNJARO, QULIPTA, FREESTYLE LIBRE 3, GARDASIL 9, VRAYLAR, ELIQUIS, XIFAXAN.
Industry payments across DE — which companies pay providers there.
